Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection

Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Victor Chien-Chia, Li, Yan-Rong, Wang, Chao-Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268177/
https://www.ncbi.nlm.nih.gov/pubmed/34281221
http://dx.doi.org/10.3390/ijms22137170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268177/
https://www.ncbi.nlm.nih.gov/pubmed/34281221
http://dx.doi.org/10.3390/ijms22137170

Ejemplares similares